Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Horm Behav. 2016 Oct 26;87:8–15. doi: 10.1016/j.yhbeh.2016.10.011

Table 1.

Developmental milestones. Age at eye opening was not affected by treatment in males or females. Vaginal opening (VO) in females and preputial separation (PPS) in males were used as markers of puberty. VO was unaffected by treatment in females. A1221 (1.0) slightly but significantly advanced PPS compared to DMSO (*p < 0.05). Treatment did not have an effect on circulating testosterone in males. Data shown are mean ± SEM.

Treatment Females Males
Mean ± SEM Mean ± SEM
Eye opening (PND) DMSO 15.24 ± 0.10 15.35 ± 0.10
EB 15.08 ± 0.11 15.35 ± 0.10
A1221 (0.5) 15.01 ± 0.10 15.15 ± 0.08
A1221 (1.0) 14.97 ± 0.07 15.12 ± 0.08
Puberty (PND) DMSO 34.79 ± 0.28 43.52 ± 0.26
EB 34.86 ± 0.32 42.93 ± 0.23
A1221 (0.5) 34.66 ± 0.19 43.00 ± 0.19
A1221 (1.0) 34.16 ± 0.31 42.51 ± 0.20*
Testosterone (ng/ml) DMSO 0.93 ± 0.22
EB 0.75 ± 0.11
A1221 (0.5) 0.76 ± 0.09
A1221 (1.0) 0.76 ± 0.10